Imatinib in Patients with Aggressive Fibromatosis and Pigmented Villonodular Synovitis: A Systematic Review
- سال انتشار: 1400
- محل انتشار: مجله بین المللی پزشکی رضوی، دوره: 9، شماره: 2
- کد COI اختصاصی: JR_RIJO-9-2_001
- زبان مقاله: انگلیسی
- تعداد مشاهده: 391
نویسندگان
Firrozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran.
Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran
Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, IR Iran
Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, IR Iran
چکیده
Introduction: We undertook a systematic review of the literature to determine the efficacy and safety of Imatinib in the restriction of activity and effective treatment of patients with aggressive fibromatosis (AF) and pigmented villonodular synovitis (PVNS) and their recurrence. Method: We searched studies in the PubMed and Cochrane collaborative library at all levels from ۲۰۱۰ to April ۲۰۱۹. Two independent reviewers evaluated the articles according to the predefined criteria and extracted the related data. Primary outcomes associated with tumor size shrinkage, relapse and overall survival along with secondary outcomes such as pain, quality of life, and side effects were investigated. Results: ۱۱۲ studies were evaluated out of which only ۶ studies that covered original studies and case reports were entered into this systematic review. A total of ۷۹subjects had participated in these six studies with an age range of ۲۲ to ۴۱ years old. In five studies, participants had a primary tumor and in one research they reported relapse. The recommended dose was ۴۰۰ mg/day, which was usually continued for ۴ to ۱۲ months. The tumor size shrinkage and low side effects of drugs have been reported. Conclusion: According to the results, no systemic treatment for PVNS and AF has been approved so far, but many studies have demonstrated the efficacy of Imatinib in the treatment of these diseases. However, further studies are required for optimal treatment and combined therapies.کلیدواژه ها
Imatinib, aggressive fibromatosis, pigmented villonodular synovitis, Recurrence, Desmoids tumorاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.